|
🐜
|
Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma).
7 auth.
P. Anderson,
Lisa M. Kopp,
N. Anderson,
K. Cornelius,
C. Herzog,
D. Hughes,
...
W. Huh
|
5 |
2008 |
5
🐜
|
|
🐜
|
Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma)
7 auth.
P. Anderson,
Lisa M. Kopp,
N. Anderson,
K. Cornelius,
C. Herzog,
D. Hughes,
...
W. Huh
|
5 |
2008 |
5
🐜
|
|
🐜
|
Increased nm23 immunoreactivity is associated with selective inhibition of systemic tumour cell dissemination.
8 auth.
A. Graham,
P. Maxwell,
K. Mulholland,
A. Patterson,
N. Anderson,
K. McManus,
...
H. Bharucha,
J. Mcguigan
|
3 |
2002 |
3
🐜
|
|
🦁
|
Abstract 4053: A mesothelin targeting chimeric antigen receptor macrophage (CAR-M) for solid tumor immunotherapy: pre-clinical development of CT-1119
12 auth.
N. Anderson,
Brinda Shah,
Alison Worth,
R. Gabbasov,
Brett Menchel,
Kerri Ciccaglione,
...
D. Blumenthal,
S. Pierini,
S. DeLong,
S. Abramson,
T. Condamine,
M. Klichinsky
|
0 |
2023 |
0
🦁
|
